Targeted Cancer Drugs Market Analysed by Espicom in New Topical Report Now Available at

27 Feb 2012 • by Natalie Aster

LONDON – The end of 2011 saw the US approval of two new molecularly-targeted cancer drugs, alongside companion diagnostic tests that identify the patients most likely to benefit from treatment. Pfizer's Xalkori (crizotinib) and Roche's Zelboraf (vemurafenib) were both approved following a priority review, highlighting the importance that the FDA has placed on hastening the passage of these therapies to market.

With sales of many blockbuster drugs being cannibalised by generic competitors, pharmaceutical and biotechnology companies are populating their pipelines with candidates directed at novel targets, enhancing development and commercialisation potential. The opportunities for small and medium-sized companies is increasing as the dynamic of the market changes.

New market research study "Targeted Cancer Drugs: The Launch Landscape to 2018" prepared by Espicom examines the current market for targeted cancer drugs, with an overview of both products and players. It covers statistics, competitive rankings, timelines and sector share comparisons. Looking ahead, the report identifies 79 new candidates that are currently under a minimum of Phase II development for solid tumours and provides a timeline detailing estimated launch dates to 2018.

Report Details:

Targeted Cancer Drugs: The Launch Landscape to 2018
Published: February, 2012
Pages: 306
Price: US$ 2.265,00

More new market research reports by the publisher can be found at Espicom page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970